RCKTW — Rocket Pharmaceuticals, Inc. Warrant

Rocket Pharmaceuticals, Inc. Warrant (RCKTW) is a biotechnology company listed on NASDAQ. It is with about 240 employees. Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure. It has license agreements with Fred Hutchinson Cancer Research Center; Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. The company is headquartered in Cranbury, New Jersey.

Latest reported RCKTW revenue for 2025-09-30 was $0. Net income was -$50.3M.

Use this RCKTW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RCKTW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RCKTW SEC filings page. Lician reads the product cache first so this HTML stays unique to Rocket Pharmaceuticals, Inc. Warrant even when a live quote feed is slow.